Literature DB >> 15467431

PRL-3: a phosphatase for metastasis?

Jason A Sager1, Silvia Benvenuti, Alberto Bardelli.   

Abstract

The PRL-3 phosphatase has joined the cancer arena very recently but is rapidly gaining interest both as a putative prognostic factor and as a therapeutic target for metastatic tumors. In this issue Guo and colleagues provide another key piece of information by showing that the catalytic activity of PRL-3 is required for experimental metastasis formation in mouse models. Here we summarize the current knowledge and discuss what remains to be done before PRL-3 could be considered as a target for diagnostics or therapeutics in the clinical setting of human cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467431     DOI: 10.4161/cbt.3.10.1115

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  9 in total

1.  Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.

Authors:  Zhao Wang; Shi-Rong Cai; Yu-Long He; Wen-Hua Zhan; Chang-Hua Zhang; Hui Wu; Jian-Jun Peng; Jian-Bo Xu; Xin-Hua Zhang; Liang Wang; Wu Song
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-09       Impact factor: 4.553

2.  Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.

Authors:  Ni Dai; Ai-Ping Lu; Cheng-Chao Shou; Ji-You Li
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

3.  Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase.

Authors:  Fubo Liang; Yong Luo; Yuanshu Dong; Chad D Walls; Jiao Liang; Hao-Yuan Jiang; Jeremy R Sanford; Ronald C Wek; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2008-02-11       Impact factor: 5.157

4.  Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Authors:  Unn-Merete Fagerli; Randi U Holt; Toril Holien; Thea K Vaatsveen; Fenghuang Zhan; Kjartan W Egeberg; Bart Barlogie; Anders Waage; Harald Aarset; Hong Yan Dai; John D Shaughnessy; Anders Sundan; Magne Børset
Journal:  Blood       Date:  2007-10-12       Impact factor: 22.113

5.  Expression of NF-κB p65 phosphorylated at serine-536 in rectal cancer with or without preoperative radiotherapy.

Authors:  Andreas Lewander; Jinfang Gao; Gunnar Adell; Hong Zhang; Xiao-Feng Sun
Journal:  Radiol Oncol       Date:  2011-09-22       Impact factor: 2.991

6.  Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.

Authors:  Reuven Reich; Shany Hadar; Ben Davidson
Journal:  Int J Mol Sci       Date:  2011-02-11       Impact factor: 5.923

7.  VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C.

Authors:  Jianliang Xu; Shaoxian Cao; Lu Wang; Rui Xu; Gong Chen; Qiang Xu
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

8.  Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition.

Authors:  Yoonho Shin; Gi Dae Kim; Ju-eun Jeon; Jongheon Shin; Sang Kook Lee
Journal:  Mar Drugs       Date:  2013-07-15       Impact factor: 5.118

9.  Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.

Authors:  Sigve Andersen; Elin Richardsen; Mehrdad Rakaee; Helena Bertilsson; Roy Bremnes; Magne Børset; Lill-Tove Busund; Tobias Slørdahl
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.